Literature DB >> 22214850

Monocyte tissue factor-dependent activation of coagulation in hypercholesterolemic mice and monkeys is inhibited by simvastatin.

A Phillip Owens1, Freda H Passam, Silvio Antoniak, Stephanie M Marshall, Allison L McDaniel, Lawrence Rudel, Julie C Williams, Brian K Hubbard, Julie-Ann Dutton, Jianguo Wang, Peter S Tobias, Linda K Curtiss, Alan Daugherty, Daniel Kirchhofer, James P Luyendyk, Patrick M Moriarty, Shanmugam Nagarajan, Barbara C Furie, Bruce Furie, Douglas G Johns, Ryan E Temel, Nigel Mackman.   

Abstract

Hypercholesterolemia is a major risk factor for atherosclerosis. It also is associated with platelet hyperactivity, which increases morbidity and mortality from cardiovascular disease. However, the mechanisms by which hypercholesterolemia produces a procoagulant state remain undefined. Atherosclerosis is associated with accumulation of oxidized lipoproteins within atherosclerotic lesions. Small quantities of oxidized lipoproteins are also present in the circulation of patients with coronary artery disease. We therefore hypothesized that hypercholesterolemia leads to elevated levels of oxidized LDL (oxLDL) in plasma and that this induces expression of the procoagulant protein tissue factor (TF) in monocytes. In support of this hypothesis, we report here that oxLDL induced TF expression in human monocytic cells and monocytes. In addition, patients with familial hypercholesterolemia had elevated levels of plasma microparticle (MP) TF activity. Furthermore, a high-fat diet induced a time-dependent increase in plasma MP TF activity and activation of coagulation in both LDL receptor-deficient mice and African green monkeys. Genetic deficiency of TF in bone marrow cells reduced coagulation in hypercholesterolemic mice, consistent with a major role for monocyte-derived TF in the activation of coagulation. Similarly, a deficiency of either TLR4 or TLR6 reduced levels of MP TF activity. Simvastatin treatment of hypercholesterolemic mice and monkeys reduced oxLDL, monocyte TF expression, MP TF activity, activation of coagulation, and inflammation, without affecting total cholesterol levels. Our results suggest that the prothrombotic state associated with hypercholesterolemia is caused by oxLDL-mediated induction of TF expression in monocytes via engagement of a TLR4/TLR6 complex.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22214850      PMCID: PMC3266787          DOI: 10.1172/JCI58969

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  70 in total

1.  Simvastatin reduces monocyte-tissue-factor expression type IIa hypercholesterolaemia.

Authors:  D Ferro; S Basili; C Alessandri; B Mantovani; C Cordova; F Violi
Journal:  Lancet       Date:  1997-10-25       Impact factor: 79.321

Review 2.  Atherosclerosis--an inflammatory disease.

Authors:  R Ross
Journal:  N Engl J Med       Date:  1999-01-14       Impact factor: 91.245

3.  Disruption of the 12/15-lipoxygenase gene diminishes atherosclerosis in apo E-deficient mice.

Authors:  T Cyrus; J L Witztum; D J Rader; R Tangirala; S Fazio; M F Linton; C D Funk
Journal:  J Clin Invest       Date:  1999-06       Impact factor: 14.808

4.  Statins decrease Toll-like receptor 4 expression and downstream signaling in human CD14+ monocytes.

Authors:  Heiko Methe; Jong-Oh Kim; Sieglinde Kofler; Michael Nabauer; Michael Weis
Journal:  Arterioscler Thromb Vasc Biol       Date:  2005-04-28       Impact factor: 8.311

5.  Active site inhibited factor VIIa (DEGR VIIa) attenuates the coagulant and interleukin-6 and -8, but not tumor necrosis factor, responses of the baboon to LD100 Escherichia coli.

Authors:  F B Taylor; A C Chang; G Peer; A Li; M Ezban; U Hedner
Journal:  Blood       Date:  1998-03-01       Impact factor: 22.113

6.  Simvastatin blunts endotoxin-induced tissue factor in vivo.

Authors:  Sabine Steiner; Walter S Speidl; Johannes Pleiner; Daniela Seidinger; Gerlinde Zorn; Christoph Kaun; Johann Wojta; Kurt Huber; Erich Minar; Michael Wolzt; Christoph W Kopp
Journal:  Circulation       Date:  2005-04-12       Impact factor: 29.690

7.  Low levels of tissue factor are compatible with development and hemostasis in mice.

Authors:  G C Parry; J H Erlich; P Carmeliet; T Luther; N Mackman
Journal:  J Clin Invest       Date:  1998-02-01       Impact factor: 14.808

8.  Macrovascular thrombosis is driven by tissue factor derived primarily from the blood vessel wall.

Authors:  Sharlene M Day; Jennifer L Reeve; Brian Pedersen; Diana M Farris; Daniel D Myers; Michael Im; Thomas W Wakefield; Nigel Mackman; William P Fay
Journal:  Blood       Date:  2004-08-31       Impact factor: 22.113

9.  Hematopoietic cell-derived microparticle tissue factor contributes to fibrin formation during thrombus propagation.

Authors:  Janet Chou; Nigel Mackman; Glenn Merrill-Skoloff; Brian Pedersen; Barbara C Furie; Bruce Furie
Journal:  Blood       Date:  2004-07-27       Impact factor: 22.113

10.  Oxidized LDL and malondialdehyde-modified LDL in patients with acute coronary syndromes and stable coronary artery disease.

Authors:  P Holvoet; J Vanhaecke; S Janssens; F Van de Werf; D Collen
Journal:  Circulation       Date:  1998-10-13       Impact factor: 29.690

View more
  74 in total

1.  LNK/SH2B3 Loss of Function Promotes Atherosclerosis and Thrombosis.

Authors:  Wei Wang; Yang Tang; Ying Wang; Liana Tascau; Joanna Balcerek; Wei Tong; Ross L Levine; Carrie Welch; Alan R Tall; Nan Wang
Journal:  Circ Res       Date:  2016-07-18       Impact factor: 17.367

2.  The disulfide isomerase ERp57 is required for fibrin deposition in vivo.

Authors:  J Zhou; Y Wu; L Wang; L Rauova; V M Hayes; M Poncz; D W Essex
Journal:  J Thromb Haemost       Date:  2014-09-26       Impact factor: 5.824

3.  Oxidized LDL Levels Are Increased in HIV Infection and May Drive Monocyte Activation.

Authors:  David A Zidar; Steven Juchnowski; Brian Ferrari; Brian Clagett; Heather A Pilch-Cooper; Shawn Rose; Benigno Rodriguez; Grace A McComsey; Scott F Sieg; Nehal N Mehta; Michael M Lederman; Nicholas T Funderburg
Journal:  J Acquir Immune Defic Syndr       Date:  2015-06-01       Impact factor: 3.731

4.  Regulation of tissue factor gene expression in monocytes and endothelial cells: Thromboxane A2 as a new player.

Authors:  Michael Bode; Nigel Mackman
Journal:  Vascul Pharmacol       Date:  2014-05-21       Impact factor: 5.773

5.  Associations of ApoAI and ApoB-containing lipoproteins with AngII-induced abdominal aortic aneurysms in mice.

Authors:  Jing Liu; Hong Lu; Deborah A Howatt; Anju Balakrishnan; Jessica J Moorleghen; Mary Sorci-Thomas; Lisa A Cassis; Alan Daugherty
Journal:  Arterioscler Thromb Vasc Biol       Date:  2015-06-04       Impact factor: 8.311

6.  Thrombin promotes diet-induced obesity through fibrin-driven inflammation.

Authors:  Anna K Kopec; Sara R Abrahams; Sherry Thornton; Joseph S Palumbo; Eric S Mullins; Senad Divanovic; Hartmut Weiler; A Phillip Owens; Nigel Mackman; Ashley Goss; Joanne van Ryn; James P Luyendyk; Matthew J Flick
Journal:  J Clin Invest       Date:  2017-07-24       Impact factor: 14.808

Review 7.  Sources of tissue factor that contribute to thrombosis after rupture of an atherosclerotic plaque.

Authors:  A Phillip Owens; Nigel Mackman
Journal:  Thromb Res       Date:  2012-03-22       Impact factor: 3.944

8.  The effect and molecular mechanism of statins on the expression of human anti-coagulation genes.

Authors:  Sheng-Nan Chang; Cho-Kai Wu; Ling-Ping Lai; Fu-Tien Chiang; Juey-Jen Hwang; Chia-Ti Tsai
Journal:  Cell Mol Life Sci       Date:  2019-05-03       Impact factor: 9.261

9.  Therapeutic administration of the direct thrombin inhibitor argatroban reduces hepatic inflammation in mice with established fatty liver disease.

Authors:  Karen M Kassel; Bradley P Sullivan; Wei Cui; Bryan L Copple; James P Luyendyk
Journal:  Am J Pathol       Date:  2012-07-26       Impact factor: 4.307

Review 10.  New players in haemostasis and thrombosis.

Authors:  Julia E Geddings; Nigel Mackman
Journal:  Thromb Haemost       Date:  2014-02-27       Impact factor: 5.249

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.